Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 307,584 | 197,538 | 290,875 | 383,794 | 713,526 |
| Marketable Securities | 432,612 | 539,579 | 554,881 | 581,614 | 488,007 |
| Receivables | 28,432 | 25,383 | 24,720 | 25,032 | 23,093 |
| Inventories | 16,231 | 15,191 | 15,083 | 12,462 | 13,048 |
| TOTAL | $856,604 | $846,884 | $949,492 | $1,070,936 | $1,295,304 |
| Non-Current Assets | |||||
| PPE Net | 141,247 | 119,069 | 104,568 | 87,570 | 73,515 |
| Investments And Advances | 293,858 | 290,458 | 231,741 | 216,380 | 165,881 |
| Intangibles | 175,194 | 175,275 | 175,356 | 175,437 | 175,519 |
| Other Non-Current Assets | 55,494 | 53,115 | 51,287 | 47,440 | 49,336 |
| TOTAL | $665,793 | $637,917 | $562,952 | $526,827 | $464,251 |
| Total Assets | $1,522,397 | $1,484,801 | $1,512,444 | $1,597,763 | $1,759,555 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 17,138 | 15,575 | 21,790 | 15,744 | 12,923 |
| Accrued Expenses | 145,555 | 109,660 | 91,060 | 82,699 | 108,491 |
| Other current liabilities | 7,609 | N/A | 3,912 | 19,221 | 59,219 |
| TOTAL | $181,368 | $135,933 | $127,067 | $127,044 | $189,609 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 385,162 | 381,888 | 379,900 | 382,831 | 382,265 |
| TOTAL | $418,468 | $415,194 | $413,206 | $416,137 | $415,571 |
| Total Liabilities | $599,836 | $551,127 | $540,273 | $543,181 | $605,180 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 69,385 | 68,162 | 67,836 | 67,483 | 66,949 |
| Common Shares | 69 | 68 | 68 | 67 | 67 |
| Retained earnings | -2,073,601 | -1,951,143 | -1,878,145 | -1,755,717 | -1,619,576 |
| Other shareholders' equity | -1,404 | 54 | 232 | 56 | 689 |
| TOTAL | $922,561 | $933,674 | $972,171 | $1,054,582 | $1,154,375 |
| Total Liabilities And Equity | $1,522,397 | $1,484,801 | $1,512,444 | $1,597,763 | $1,759,555 |